Levepipe

White crystalline powder filled in 30 mL colorless USP Type-II glass with 20 mm standard mount finish, plugged with 20 mm grey butyl rubber stopper and sealed with 20 mm blue colour aluminium flip off seal.
Each vial contains: Piperacillin (as sodium) USP 4 g.
Tazobactam (as sodium) USP 500 mg.

Penicillins.
Pharmacology: Pharmacodynamics: Mode of Action: Piperacillin sodium/tazobactam sodium is an injectable antibacterial combination consisting of the semisynthetic antibiotic piperacillin sodium and the β-lactamase inhibitor tazobactam sodium for intravenous administration. Thus, piperacillin/tazobactam combines the properties of a broad-spectrum antibiotic and a β-lactamase inhibitor.
Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis. Piperacillin and other β-lactam antibiotics block the terminal transpeptidation step of cell wall peptidoglycan biosynthesis in susceptible organisms by interacting with penicillin-binding proteins (PBPs), the bacterial enzymes that carry out this reaction. In vitro, piperacillin is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria. Piperacillin has reduced activity against bacteria harboring certain β-lactamase enzymes, which chemically inactivate piperacillin and other β-lactam antibiotics. Tazobactam sodium, which has very little intrinsic antimicrobial activity, due to its low affinity for PBPs, can restore or enhance the activity of piperacillin against many of these resistant organisms. Tazobactam is a potent inhibitor of many class A β-lactamases (penicillinases, cephalosporinases and extended spectrum enzymes). It has variable activity against class A carbapenemases and class D β-lactamases. It is not active against most class C cephalosporinases and inactive against Class B metallo-β-lactamases.
Two features of piperacillin/tazobactam lead to increased activity against some organisms harboring β-lactamases that, when tested as enzyme preparations, are less inhibited by tazobactam and other inhibitors: tazobactam does not induce chromosomally mediated β-lactamases at tazobactam levels achieved with the recommended dosing regimen and piperacillin is relatively refractory to the action of some β-lactamases.
Like other β-lactam antibiotics, piperacillin, with or without tazobactam, demonstrates time-dependent bactericidal activity against susceptible organisms.
Mechanism of Resistance: There are three major mechanisms of resistance to β-lactam antibiotics: changes in the target PBPs resulting in reduced affinity for the antibiotics, destruction of the antibiotics by bacterial β-lactamases, and low intracellular antibiotic levels due to reduced uptake or active efflux of the antibiotics.
In gram-positive bacteria, changes in PBPs are the primary mechanism of resistance to β-lactam antibiotics, including piperacillin/tazobactam. This mechanism is responsible for methicillin resistance in staphylococci and penicillin resistance in Streptococcus pneumoniae and viridans group streptococci.
Resistance caused by changes in PBPs also occurs in fastidious gram-negative species such as Haemophilus influenzae and Neisseria gonorrhoeae. Piperacillin/tazobactam is not active against strains in which resistance to β-lactam antibiotics is determined by altered PBPs. As indicated previously, there are some β-lactamases that are not inhibited by tazobactam.
Methodology for Determining the In Vitro Susceptibility of Bacteria to Piperacillin/Tazobactam: Susceptibility testing should be conducted using standardized laboratory methods, such as those described by the Clinical and Laboratory Standards Institute (CLSI). These include dilution methods (minimal inhibitory concentration [MIC] determination) and disk susceptibility methods. Both CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) provide susceptibility interpretive criteria for some bacterial species based on these methods. It should be noted that for the disk diffusion method, CLSI and EUCAST use disks with different drug contents.
The CLSI interpretive criteria for susceptibility testing of piperacillin/tazobactam are listed in Table 1 (see Table 1).

Click on icon to see table/diagram/image

Standardized susceptibility test procedures require the use of quality control microorganisms to control the technical aspects of the test procedures. Quality control microorganisms are specific strains with intrinsic biological properties relating to resistance mechanisms and their genetic expression within the microorganism; the specific strains used for susceptibility test quality control are not clinically significant. Organisms and quality control ranges for piperacillin/tazobactam to be utilized with CLSI methodology and susceptibility test interpretative criteria are listed in Table 2 (see Table 2).

Click on icon to see table/diagram/image

EUCAST has also established clinical breakpoints for piperacillin/tazobactam against some organisms. Like CLSI, the EUCAST MIC susceptibility criteria are based on a fixed concentration of 4 mg/L of tazobactam. However, for inhibition zone determination, the disks contain 30 µg of piperacillin and 6 µg of tazobactam. The EUCAST rationale document for piperacillin/tazobactam states that breakpoints for Pseudomonas aeruginosa apply to dosages of 4 g, 4 times daily, whereas the breakpoints for other organisms are based on 4 g, 3 times daily.
The EUCAST breakpoints for piperacillin/tazobactam are listed in Table 3 (see Table 3).

Click on icon to see table/diagram/image

Per EUCAST, for species without piperacillin/tazobactam breakpoints, susceptibility in staphylococci is inferred from cefoxitin/oxacillin susceptibility. For groups A, B, C and G streptococci and Streptococcus pneumoniae, susceptibility is inferred from benzylpenicillin susceptibility. For other streptococci, enterococci and β-lactamase negative Haemophilus influenzae, susceptibility is inferred from amoxicillin-clavulanate susceptibility. There are no EUCAST breakpoints for Acinetobacter. The EUCAST rationale document for piperacillin/tazobactam states that in endocarditis caused by streptococci other than groups A, B, C and S. pneumoniae, national or international guidelines should be referred to Quality control ranges for EUCAST susceptibility breakpoints are listed in Table 4 (see Table 4).

Click on icon to see table/diagram/image

Antibacterial Spectrum: Piperacillin/tazobactam has been shown to be active against most strains of the following microorganisms, both in vitro and in the indicated clinical infections. Aerobic and facultative gram-positive microorganisms: Staphylococcus aureus (methicillin-susceptible strains only). Aerobic and facultative gram-negative microorganisms: Acinetobacter baumannii, Escherichia coli, Haemophilus influenzae (excluding β-lactamase negative, ampicillin-resistant isolates), Klebsiella pneumoniae, Pseudomonas aeruginosa (given in combination with an aminoglycoside to which the isolate is susceptible).
Gram-negative anaerobes: Bacteroides fragilis group (B. fragilis, B. ovatus, B. thetaiotaomicron, and B. vulgatus). The following in vitro data are available, but their clinical significance is unknown. At least 90% of the following microorganisms exhibit an in vitro MIC less than or equal to the susceptible breakpoint for piperacillin/tazobactam. However, the safety and effectiveness of piperacillin/tazobactam in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.
Aerobic and facultative gram-positive microorganisms: Enterococcus faecalis (ampicillin- or penicillin-susceptible isolates only), Staphylococcus epidermidis (methicillin-susceptible isolates only), Streptococcus agalactiae⁺, Streptococcus pneumoniae⁺ (penicillin-susceptible isolates only), Streptococcus pyogenes⁺, Viridans group streptococci.
Aerobic and facultative gram-negative microorganisms: Citrobacter koseri, Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, Proteus mirabilis, Proteus vulgaris, Serratia marcescens, Providencia stuartii, Providencia rettgeri, Salmonella enterica.
Gram-positive anaerobes: Clostridium perfringens.
Gram-negative anaerobes: Bacteroides distasonis, Prevotella melaninogenica.
+These are not β-lactamase producing bacteria and, therefore, are susceptible to piperacillin alone.
Pharmacokinetics: Distribution: Both piperacillin and tazobactam are approximately 30% bound to plasma proteins. The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound. Protein binding of the tazobactam metabolite is negligible.
Piperacillin/tazobactam is widely distributed in tissues and body fluids including intestinal mucosa, gallbladder, lung, bile, and bone. Mean tissue concentrations are generally 50% to 100% of those in plasma.
Metabolism: Piperacillin is metabolized to a minor microbiologically active desethyl metabolite. Tazobactam is metabolized to a single metabolite that has been found to be microbiologically inactive.
Elimination: Piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion. Piperacillin is excreted rapidly as unchanged drug with 68% of the administered dose appearing in the urine. Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the administered dose appearing as unchanged drug and the remainder as the single metabolite. Piperacillin, tazobactam, and desethyl piperacillin are also secreted into the bile. Following administration of single or multiple doses of piperacillin/tazobactam to healthy subjects, the plasma half-life of piperacillin and tazobactam ranged from 0.7 to 1.2 hours and was unaffected by dose or duration of infusion.
The elimination half-lives of both piperacillin and tazobactam are increased with decreasing renal clearance.
There are no significant changes in the pharmacokinetics of piperacillin due to tazobactam. Piperacillin appears to reduce the rate of elimination of tazobactam.
Special Populations: The half-lives of piperacillin and of tazobactam increase by approximately 25% and 18%, respectively, in patients with hepatic cirrhosis compared to healthy subjects. The half-lives of piperacillin and tazobactam increase with decreasing creatinine clearance. The increase in half-life is two-fold and four-fold for piperacillin and tazobactam, respectively, at creatinine clearance below 20 mL/min compared to patients with normal renal function. Hemodialysis removes 30% to 50% of piperacillin/tazobactam with an additional 5% of the tazobactam dose removed as the tazobactam metabolite. Peritoneal dialysis removes approximately 6% and 21% of the piperacillin and tazobactam doses, respectively, with up to 18% of the tazobactam dose removed as the tazobactam metabolite.
Toxicology: Preclinical Safety Data: Carcinogenicity: Carcinogenicity studies have not been conducted with piperacillin, tazobactam, or the combination.
Mutagenicity: Piperacillin/tazobactam was negative in microbial mutagenicity assays. Piperacillin/tazobactam was negative in the unscheduled DNA synthesis (UDS) test. Piperacillin/tazobactam was negative in a mammalian point mutation (Chinese hamster ovary cell hypoxanthine phosphoribosyltransferase [HPRT]) assay.
Piperacillin/tazobactam was negative in a mammalian cell (BALB/c-3T3) transformation assay. In vivo, piperacillin/tazobactam did not induce chromosomal aberrations in rats dosed intravenously. Piperacillin was negative in microbial mutagenicity assays. There was no DNA damage in bacteria (Rec assay) exposed to piperacillin. Piperacillin was negative in the UDS test. In a mammalian point mutation (mouse lymphoma cells) assay, piperacillin was positive. Tazobactam was negative in microbial mutagenicity assays. Tazobactam was negative in the UDS test. Tazobactam was negative in a mammalian point mutation (Chinese hamster ovary cell HPRT) assay. In another mammalian point mutation (mouse lymphoma cells) assay, tazobactam was positive. Tazobactam was negative in a cell (BALB/c-3T3) transformation assay. In an in vitro cytogenetics (Chinese hamster lung cells) assay, tazobactam was negative. In vivo, tazobactam did not induce chromosomal aberrations in rats dosed intravenously.
Reproductive Toxicity: In embryo-fetal development studies, there was no evidence of teratogenicity following intravenous administration of tazobactam or the pipericillin/tazobactam combination; however, in rats there were slight reductions in fetal body weight at maternally toxic doses. Intraperitoneal administration of piperacillin/tazobactam was associated with slight reductions in litter size and an increased incidence of minor skeletal anomalies (delays in bone ossification) at doses that produced maternal toxicity.
Peri-/post-natal development was impaired (reduced pup weights, increase in stillbirth, increase in pup mortality), concurrent with maternal toxicity.
Impairment of Fertility: Reproduction studies in rats revealed no evidence of impaired fertility due to tazobactam or piperacillin/tazobactam when administered intraperitoneally.

For the treatment of intra-abdominal infections, skin and skin structures infections, female pelvic infections, community-acquired pneumonia and nosocomial pneumonia.

Piperacillin/Tazobactam should be administered by intravenous infusion over 30 minutes.
Adults: The usual total daily dose of Piperacillin/Tazobactam is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam). Initial presumptive treatment of patients with nosocomial pneumonia should start with (16.0 g piperacillin/2.0 g tazobactam). Treatment with aminoglycoside should be continued in patients from whom Pseudomonas aeruginosa is isolated. If Pseudomonas aeruginosa is not isolated, the aminoglycoside may be discontinued at the discretion of the treating physician.
Pediatrics: Piperacillin/Tazobactam can be administered in pediatric patients from 2 months of age. The dosage and indications in pediatric patients with normal renal function are as follows:
Direction for Reconstitution: 4.5 g Piperacillin and Tazobactam for injection should be reconstituted with 20 mL of Sterile Water for Injection respectively swirl dissolved. Discard any unused portion.
For conventional vials, reconstitute Piperacillin and Tazobactam for Injection per gram of piperacillin with 5 mL of compatible.
Sterile Water/diluents for reconstitution. Shake well until dissolved. Discard any unused portion. Shake Well Before Use. (See Table 5.)

Click on icon to see table/diagram/image

Symptoms: There have been post-marketing reports of overdosage with piperacillin/tazobactam. The majority of those events experienced including nausea, vomiting and diarrhea have also been reported with the usual recommended dosages. Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given IV (particularly in the presence of renal failure).
Treatment: Treatment should be supportive and symptomatic according to the patient's clinical presentation.
No specific antidote is known. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by hemodialysis.

Hypersensitivity.

Pregnancy, lactation, taking any prescription or non-prescription medicine, herbal preparation, or dietary supplement, allergies to medicines, food or other substances, cystic fibrosis, bowel inflammation, bleeding problems, congestive heart failure, kidney problems, history of severe diarrhea or bowel problems with antibiotics, on a salt-restricted diet or low blood potassium levels.

Agitation, constipation, diarrhea, dizziness, headache, indigestion, nausea, pain, swelling or redness at the injection site, sleeplessness, vomiting.

Aminoglycosides, oral contraceptives, anticoagulants, heparin, methotrexate, non-depolarizing muscle relaxants, probenecid, tetracyclines.

Store at temperatures not exceeding 30°C.
Protected from light and moisture.

Penicillins

J01CR05 - piperacillin and beta-lactamase inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections.

Rx